IL298314B2 - Methods of administration and methods of treating cardiovascular diseases with resiniparatoxin - Google Patents

Methods of administration and methods of treating cardiovascular diseases with resiniparatoxin

Info

Publication number
IL298314B2
IL298314B2 IL298314A IL29831422A IL298314B2 IL 298314 B2 IL298314 B2 IL 298314B2 IL 298314 A IL298314 A IL 298314A IL 29831422 A IL29831422 A IL 29831422A IL 298314 B2 IL298314 B2 IL 298314B2
Authority
IL
Israel
Prior art keywords
hypertension
trpv1
receptor agonist
treatment
subject
Prior art date
Application number
IL298314A
Other languages
English (en)
Hebrew (he)
Other versions
IL298314B1 (en
IL298314A (en
Inventor
Irving H Zucker
Hanjun Wang
Original Assignee
Univ Nebraska
Irving H Zucker
Hanjun Wang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nebraska, Irving H Zucker, Hanjun Wang filed Critical Univ Nebraska
Publication of IL298314A publication Critical patent/IL298314A/en
Publication of IL298314B1 publication Critical patent/IL298314B1/en
Publication of IL298314B2 publication Critical patent/IL298314B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL298314A 2016-04-13 2017-04-13 Methods of administration and methods of treating cardiovascular diseases with resiniparatoxin IL298314B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662322079P 2016-04-13 2016-04-13
PCT/US2017/027480 WO2017180907A1 (en) 2016-04-13 2017-04-13 Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin

Publications (3)

Publication Number Publication Date
IL298314A IL298314A (en) 2023-01-01
IL298314B1 IL298314B1 (en) 2024-12-01
IL298314B2 true IL298314B2 (en) 2025-04-01

Family

ID=60039929

Family Applications (2)

Application Number Title Priority Date Filing Date
IL298314A IL298314B2 (en) 2016-04-13 2017-04-13 Methods of administration and methods of treating cardiovascular diseases with resiniparatoxin
IL262328A IL262328B2 (en) 2016-04-13 2017-04-13 Methods for administration and methods for treating cardiovascular diseases with resiniparatoxin

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL262328A IL262328B2 (en) 2016-04-13 2017-04-13 Methods for administration and methods for treating cardiovascular diseases with resiniparatoxin

Country Status (9)

Country Link
US (3) US20170296506A1 (https=)
EP (1) EP3442523A4 (https=)
JP (3) JP6980694B2 (https=)
KR (2) KR102395342B1 (https=)
CN (2) CN120114438A (https=)
AU (1) AU2017248665B2 (https=)
CA (1) CA3020815A1 (https=)
IL (2) IL298314B2 (https=)
WO (1) WO2017180907A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113490745A (zh) 2018-12-21 2021-10-08 索伦托药业有限公司 神经周施用树脂毒素治疗适应不良性疼痛
EP3914595A4 (en) 2019-01-22 2022-11-09 Sorrento Therapeutics, Inc. METHOD OF TREATMENT OF OSTEOARTHRITIS PAIN BY ADMINISTRATION OF RESINIFERATOXIN
CA3188689A1 (en) * 2020-08-11 2022-02-17 Alexis G. Nahama Treating pulmonary inflammatory disease by neural ablation
CA3219312A1 (en) * 2021-05-18 2022-11-24 Alexis Nahama Presurgical perineural administration of resiniferatoxin for reduction of post-operative pain

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8829028B2 (en) * 2002-05-16 2014-09-09 Serodus As 5-HT4 receptor antagonists for the treatment of heart failure
US20150080460A1 (en) * 2013-09-18 2015-03-19 Board Of Regents Of The University Of Nebraska Methods for Administration and Methods for Treating Cardiovascular Diseases with Resiniferatoxin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007017764A2 (en) * 2005-05-18 2007-02-15 Neuraxon, Inc. Substituted benzimidazole compounds with dual nos inhibitory activity and muopioid agonist activity
RU2432950C2 (ru) * 2006-01-25 2011-11-10 Инсис Терапьютикс Инк. Подъязычный спрей на основе фентанила
US20100158973A1 (en) * 2006-03-13 2010-06-24 Hadasit Medical Research Services & Development Llimited Therapeutic uses of cannabidiol compounds
CN101522181A (zh) * 2006-10-04 2009-09-02 纽若科伊公司 诱导低体温药物在治疗局部缺血的应用
CN101951937A (zh) * 2007-12-21 2011-01-19 赫尔辛医疗股份公司 使用伊帕瑞林刺激胃肠系统动力的方法
WO2012045587A1 (en) * 2010-10-06 2012-04-12 Celltrend Gmbh A new method for diagnosing hypertension as well as cardiomyopathies
MY172557A (en) * 2013-09-17 2019-12-02 Vectus Biosystems Ltd Compositions for the treatment of hypertension and/or fibrosis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8829028B2 (en) * 2002-05-16 2014-09-09 Serodus As 5-HT4 receptor antagonists for the treatment of heart failure
US20150080460A1 (en) * 2013-09-18 2015-03-19 Board Of Regents Of The University Of Nebraska Methods for Administration and Methods for Treating Cardiovascular Diseases with Resiniferatoxin

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PREMKUMAR LS., TARGETING TRPV1 AS AN ALTERNATIVE APPROACH TO NARCOTIC ANALGESICS TO TREAT CHRONIC PAIN CONDITIONS, 30 September 2010 (2010-09-30) *
WANG, H ET AL., THORACIC EPIDURAL ADMINISTRATION OF RESINIFERATOXIN IMPROVES CARDIAC AND AUTONOMIC DYSFUNCTION IN POST-ML RATS, 1 September 2015 (2015-09-01) *

Also Published As

Publication number Publication date
EP3442523A4 (en) 2019-12-04
EP3442523A1 (en) 2019-02-20
CN109562096A (zh) 2019-04-02
JP7341203B2 (ja) 2023-09-08
JP6980694B2 (ja) 2021-12-15
IL298314B1 (en) 2024-12-01
JP2019511536A (ja) 2019-04-25
IL262328A (en) 2018-11-29
AU2017248665B2 (en) 2023-01-05
WO2017180907A1 (en) 2017-10-19
JP2023155365A (ja) 2023-10-20
IL262328B (en) 2022-12-01
CA3020815A1 (en) 2017-10-19
US20170296506A1 (en) 2017-10-19
US20250082605A1 (en) 2025-03-13
US20220000837A1 (en) 2022-01-06
CN120114438A (zh) 2025-06-10
KR20190029511A (ko) 2019-03-20
KR102508022B1 (ko) 2023-03-10
KR20220062667A (ko) 2022-05-17
AU2017248665A1 (en) 2018-11-08
KR102395342B1 (ko) 2022-05-10
IL298314A (en) 2023-01-01
IL262328B2 (en) 2023-04-01
JP2022001608A (ja) 2022-01-06

Similar Documents

Publication Publication Date Title
US20250082605A1 (en) Methods for Administration and Methods for Treating Cardiovascular Diseases with Resiniferatoxin
Fiorelli et al. Control of post-thoracotomy pain by transcutaneous electrical nerve stimulation: effect on serum cytokine levels, visual analogue scale, pulmonary function and medication
Khalil et al. Ultrasound-guided serratus anterior plane block versus thoracic epidural analgesia for thoracotomy pain
Tong et al. Liposomal bupivacaine and clinical outcomes
Agrawal et al. Effect of intrathecal midazolam bupivacaine combination on post operative analgesia
Krutsch et al. A case report of subcutaneous peripheral nerve stimulation for the treatment of axial back pain associated with postlaminectomy syndrome
Kambakamba et al. Intraoperative adverse events during irreversible electroporation–a call for caution
Schumacher et al. Treatment of venous malformations: first experience with a new sclerosing agent–a multicenter study
Jordan et al. Electrical carotid sinus stimulation in treatment resistant arterial hypertension
Dost et al. Pain management in minimally invasive cardiac surgery: a review of current clinical evidence
Mollazadeh et al. Efficacy of intravenous acetaminophen in periimplantation pain of cardiac electronic devices: a randomized double-blinded study
Schlaich et al. New therapeutic approaches to resistant hypertension
Madhavan et al. Renal nerve stimulation for the treatment of neurocardiogenic syncope
Moore et al. Neuromodulation for chronic refractory angina
Bhatt et al. Erector Spinae Plane (ESP) Block Decreases Narcotic Requirement in Patients Undergoing Subcutaneous ICD Placement Under Sedation
Sangroula et al. Anesthesia in Laparoscopy
Lucas et al. Extracorporeal shock wave therapy and percutaneous nephrolithotripsy
Figueras et al. Local modifications in tissular conditions before PFA increases acute lesion size
Peršec et al. Modaliteti regionalne analgezije u abdominalnoj kirurgiji i kirurgiji donjih ekstremiteta-usporedba i učinkovitosti
Hernandez et al. Epidural Opioids for Postoperative Pain
Staudt et al. Neuromodulation for Non-urologic Chronic Pain
Choudhary et al. Anaesthetic management of intracranial aneurysm in patient with coarctation of aorta
Hong The effects of stellate ganglion block on intraoperative hemodynamics and postoperative side effects in laparoscopic day-case surgery
OPIOIDS Epidural Opioids for Postoperative Pain
Gaurav Comparison of onset and duration of Blockade between equipotent doses of Ropivacaine-fentanyl and bupivacaine-Fentanyl in lower abdominal surgeries under Spinal anaesthesia–a one year hospital based Randomized clinical study